State-of-the-art management of nasopharyngeal carcinoma: current and future directions

por Agulnik, M, Siu, L L
Publicado 2005

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer

por Duran, I, Moore, M J, Siu, L L
Publicado 2007

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

por Oliva, M, Spreafico, A, Taberna, M, Alemany, L, Coburn, B, Mesia, R, Siu, L L
Publicado 2019

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

por Chen, E X, Hotte, S, Hirte, H, Siu, L L, Lyons, J, Squires, M, Lovell, S, Turner, S, McIntosh, L, Seymour, L
Publicado 2014

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours

por Chen, X, Oza, A M, Kusenda, Z, Yi, Q-L, Kochman, D, Moore, M J, Davis, A J, Siu, L L
Publicado 2003

Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review

por Prawira, A, Oosting, S F, Chen, T W, delos Santos, K A, Saluja, R, Wang, L, Siu, L L, Chan, K K W, Hansen, A R
Publicado 2017

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

por Lheureux, S, Oza, A M, Laurie, S A, Halford, R, Jonker, D, Chen, E, Keller, D, Bourade, V, Wang, L, Doyle, L, Siu, L L, Goel, R
Publicado 2015

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

por Townsley, C A, Major, P, Siu, L L, Dancey, J, Chen, E, Pond, G R, Nicklee, T, Ho, J, Hedley, D, Tsao, M, Moore, M J, Oza, A M
Publicado 2006

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours

por Quintela-Fandino, M, Krzyzanowska, M, Duncan, G, Young, A, Moore, M J, Chen, E X, Stathis, A, Colomer, R, Petronis, J, Grewal, M, Webster, S, Wang, L, Siu, L L
Publicado 2013

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

por Spreafico, A, Delord, J-P, De Mattos-Arruda, L, Berge, Y, Rodon, J, Cottura, E, Bedard, P L, Akimov, M, Lu, H, Pain, S, Kaag, A, Siu, L L, Cortes, J
Publicado 2015

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

por Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Publicado 2011

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

por Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, G R, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, M-S, Hedley, D, Siu, L L
Publicado 2006

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape

por Vis, D. J., Lewin, J., Liao, R. G., Mao, M., Andre, F., Ward, R. L., Calvo, F., Teh, B. T., Camargo, A. A., Knoppers, B. M., Sawyers, C. L., Wessels, L. F. A., Lawler, M., Siu, L. L., Voest, E.
Publicado 2017

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced...

por Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S, Nuyten, D S A
Publicado 2011

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

por Diaz-Padilla, I, Siu, L L, San Pedro-Salcedo, M, Razak, A R A, Colevas, A D, Shepherd, F A, Leighl, N B, Neal, J W, Thibault, A, Liu, L, Lisano, J, Gao, B, Lawson, E B, Wakelee, H A
Publicado 2012

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibit...

por Brana, I, Berger, R, Golan, T, Haluska, P, Edenfield, J, Fiorica, J, Stephenson, J, Martin, L P, Westin, S, Hanjani, P, Jones, M B, Almhanna, K, Wenham, R M, Sullivan, D M, Dalton, W S, Gunchenko, A, Cheng, J D, Siu, L L, Gray, J E
Publicado 2014

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

por Jonker, D J, Karapetis, C S, Harbison, C, O'Callaghan, C J, Tu, D, Simes, R J, Malone, D P, Langer, C, Tebbutt, N, Price, T J, Shapiro, J, Siu, L L, Wong, R P W, Bjarnason, G, Moore, M J, Zalcberg, J R, Khambata-Ford, S
Publicado 2014

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

por Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Publicado 2013

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

por Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., Tabernero, J.
Publicado 2022

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome

por Cher, C Y, Leung, G M K, Au, C H, Chan, T L, Ma, E S K, Sim, J P Y, Gill, H, Lie, A K W, Liang, R, Wong, K F, Siu, L L P, Tsui, C S P, So, C C, Wong, H W W, Yip, S F, Lee, H K K, Liu, H S Y, Lau, J S M, Luk, T H, Lau, C K, Lin, S Y, Kwong, Y L, Leung, A Y H
Publicado 2016